Preferential induction of fetal versus embryonic globin chains in human leukemic cell lines

Alessandro M. Gianni(University of Milan), Sergio Ottolenghi(University of Milano-Bicocca), Paola Comi(University of Milan), Giuseppe Saglio(University of Turin), C Peschle(Istituto Superiore di Sanità), E. Polli(University of Milan), Barbára Giglioni, F. Lettieri, Marco Presta(University of Brescia)

Leukemia Research

January 1, 1982

10.1016/0145-2126(82)90021-2

Cited by 8

Related Papers

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2015|740

The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells

|Cell|1993|610

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

|Leukemia|2012|440

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

|Journal of Clinical Oncology|2009|434

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

|Blood|2013|391